trial

A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly

NCTId NCT03809325
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Completed
Enrollment 225 (actual)
Sponsored by Janssen-Cilag Farmaceutica Ltda.
Primary completion 2019-07-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
225 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2018-11-21
Primary completion
2019-07-12
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Paliperidone

Sponsors

Janssen-Cilag Farmaceutica Ltda.Lead Sponsor

Sites

41 total
Brussels, BelgiumAsnières-sur-Seine, FranceCagnes-sur-Mer, FranceDax, FranceLimoges, FranceMetz, FranceMontauban, FranceMontpellier, FranceNice, FranceNovillars, FranceRennes, FranceToulon, France

Facts & assertions

4 sourced
Enrollment
225
Phase
NA
Primary Completion Date
2019-07-12
Status
COMPLETED
relationships
The graph out of here
drug
Paliperidone
drug
lead_sponsor
Janssen-Cilag Farmaceutica Ltda.
company
indication
Schizophrenia
indication
Schizophrenia
indication